<pad> In the MSM substudy, per-protocol efficacy for prevention of anal 6-month persistent vaccine type HPV infection was 94.9% (95% CI = 80.4–99.4).Duration of ProtectionIn the phase III trials, females aged 16–26 years were followed for a mean of 42 months after dose one (118). Follow-up through 8.5 years in the monovalent HPV 16 vaccine trial showed high efficacy and no decline in protection (124).Additional data on duration of protection will be available from follow-up of approximately 5,500 females enrolled in one of the phase III HPV4 trials in the Nordic countries.</s>